Minister of Investment Receives Minister Delegate for Foreign Trade and Economic Attractiveness of France    Ministry of Islamic Affairs Stresses Necessity of Wearing Mask and Social Distancing in Mosques    AFC President: The Global Event Formula 1 Reflects the Ambitious Vision of HRH the Crown Prince    UAE condemns terrorist Houthi militia attempt to target Saudi Arabia with drones    India reports 8,895 new infections of coronavirus    Germany Records 27,836 New COVID-19 Cases    Trafficking is a crime that can happen in front of our eyes: UNODC    Veteran US Republican leader Bob Dole dies aged 98    US Congressman condemned for Christmas guns photo    Nazaha arrests 250 government staff on charges of corruption    5-day Jeddah international motor show starts Today at 6 PM    MoH: Wearing mask is mandatory in crowded open areas    Lewis Hamilton wins thrilling Saudi Arabian Grand Prix    Crown Prince attends inaugural Saudi Arabian Grand Prix    Custodian of the Two Holy Mosques Sends Written Message to Sultan of Oman    Saudi Stock Exchange Main Index Ends Trading Higher at 11,142 Points    Jeddah international motor show to kick off Monday    King, Crown Prince congratulate Finland president on Independence Day    RSNF launches last warship of Sarawat Corvette Project in Spain    Saudia, CFM sign SR32 billion LEAP-1A engines purchase agreement    Deputy Governor of Hail: Hail International Rally is a practical translation of the wise leadership's support    Hail International Rally to Kick off Tomorrow    SAMI, Airbus to Form Joint Venture for Military Aviation MRO and Services    Death Toll Rises to 13 after Indonesia's Semeru Volcano Erupts    Saudi-French MoU signed, signalling new era of cultural collaboration    Crown Prince, Macron, and Mikati hold joint phone talks Saudi Arabia, France agree with Lebanon for joint work to boost its reforms, stability    Saudi Aramco, French Companies Sign Agreements    MODON Takes Part in Inlet Europe 2021 Summit in Italy    Asian Handball Federation Representatives Conclude Inspecting Sports Facilities in Eastern Region    Formula 1 STC Saudi Arabian Grand Prix 2021 Official Race to Kick off Tomorrow in Jeddah    Hamilton sets pace in free trials in Formula 1 STC Saudi Arabian Grand Prix    Invest in Saudi Arabia initiative announces partnership with F1 Saudi Grand Prix    Red Sea Immersive to provide enthralling experience: Liz Rosenthal    Duchess of Sussex wins latest court battle with Mail on Sunday publisher    Trolls join UN campaign for healthier eating, sustainable living    BIENALSUR Exhibition arrives in Jeddah at historic site of Qasr Khuzam    Saudi Hind Al-Showaier Elected Regional Director of World Federation of the Deaf    Saudi Film Commission launch its strategy to develop film and cinema sector    Bollywood superstar Salman Khan to dazzle Riyadh Season on Dec. 10    First Full International Marathon in Saudi Arabia to be Held in March 2022    Winter Wonderland Circus Amazes Audience with Thrilling Acrobatic Shows    Bollywood star's 'India got freedom in 2014' remark stirs controversy    23 Saudi women obtain favorable verdicts in 'adhl' lawsuits    Bride's fingerprint not required in revised e-marriage contract    Pilgrims Perform Dhuhr and Asr Prayers at Arafat Holy Site    Council of Senior Scholars: Muslim Brothers' Group Don't Represent Method of Islam, rather only Follows its Partisan Objectives, Violating our Graceful Religion    Eid Al-Adha Prayer Performed at the Grand Holy Mosque    Pilgrims Perform Dhuhr and Asr Prayers in Arafat Holy Site    







Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.



MSD makes headway in treating lung cancer that impacts economy
Published in The Saudi Gazette on 16 - 10 - 2016

The cost of lost productivity and toll in the economic growth as a whole, of premature cancer-related mortality will be greatly minimized, with MSD – the global healthcare leader providing innovative medicines, vaccines, therapies, health products and solutions – revealing a new clinical data showing its Keytruda immunotherapy offered big benefits in previously untreated lung cancer patients, either when given on its own or with chemotherapy.
Most measures of the cancer burden take a public health perspective. Cancer also has a significant economic impact on society.
At an international event held in Copenhagen, experts from MSD, known as Merck in the US and Canada, disclosed that Keytruda halved the risk of disease progression and cut overall deaths by 40 percent compared to chemotherapy alone in pre-selected patients whose tumors had been tested using a biomarker. And when given with two older chemotherapy drugs in non-selected patients, it was almost twice as likely to shrink tumors as chemotherapy alone.
"Chemotherapy has been the standard treatment for most patients with advanced non-small cell lung cancer for decades, but survival rates remain low," said Dr. Roger M. Perlmutter, president, Merck Research Laboratories. "Our new data suggest that Keytruda treatment can offer meaningful improvement over chemotherapy in a broad array of patients. In this sense, these studies may represent a turning point in worldwide efforts to control lung cancer. We sincerely thank the patients and the clinical investigators for their participation in our studies. Together we are working to improve the health of more and more patients with cancer."
The findings published in The New England Journal of Medicine demonstrated that Keytruda reduced the risk of progression or death by 50 percent compared to chemotherapy
Additionally, Keytruda resulted in a 40 percent reduction in the risk of death compared with chemotherapy. This finding includes the 66 patients (43.7%) on the chemotherapy arm who crossed over in-study to receive Keytruda once their cancer had progressed.
"These data ... demonstrate the potential of Keytruda to change the way non-small cell lung cancer is currently treated," said Dr. Martin Reck, head of the thoracic oncology dept., LungenClinic Grosshansdorf, Germany, and lead author of The New England Journal of Medicine paper.
The safety of Keytruda was consistent with what has been seen in previous trials among patients with metastatic non-small-cell lung cancer (NSCLC). The most common treatment-related adverse events for Keytruda were diarrhea, fatigue, and pyrexia.
Moreover, Roger Dansey, M.D., senior vice president and therapeutic area head, oncology late-stage development, Merck Research Laboratories, said "our research in immuno-oncology continues to show tremendous promise, with our goal being to extend the lives of significant numbers of patients with non-small cell lung cancer."
Merck has a robust clinical development program for Keytruda in lung cancer, with multiple registration-enabling studies currently underway. The Keytruda clinical development program includes more than 30 tumor types in more than 350 clinical trials, including more than 100 trials that combine Keytruda with other cancer treatments.
MSD's goal is to translate breakthrough science into innovative oncology medicines to help people with cancer worldwide. At MSD Oncology, "helping people fight cancer is our passion and supporting accessibility to our cancer medicines is our commitment. Our focus is on pursuing research in immuno-oncology and we are accelerating every step in the journey – from lab to clinic – to potentially bring new hope to people with cancer."
"As part of our focus on cancer, MSD is committed to exploring the potential of immuno-oncology with one of the fastest-growing development programs in the industry. We are currently executing an expansive research program that includes more than 350 clinical trials evaluating our anti-PD-1 therapy across more than 30 tumor types. We also continue to strengthen our immuno-oncology portfolio through strategic acquisitions and are prioritizing the development of several promising immunotherapeutic candidates with the potential to improve the treatment of advanced cancers," MSD said in a statement.


Clic here to read the story from its source.